Mga Batayang Estadistika
| LEI | 549300ZHL16S29QTW485 |
| CIK | 1554859 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Semler Scientific, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 4, 2025 |
Exhibit 99.1 Semler Scientific® Reports Second Quarter 2025 Financial Results, BTC Holdings of 5,021 and BTC Yield of 31.3% YTD through July 31, 2025 Campbell, CA – August 4, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, today reported financial results |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36305 SEM |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| July 24, 2025 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| June 23, 2025 |
Exhibit 3.1 fIFth AMENDED AND RESTATED BYLAWS OF SEMLER SCIENTIFIC, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of its registered agent at such address shall be as set forth in the Amended and Restated Certificate of Incorporation of the corporation (as the same may be amended and/or re |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| June 4, 2025 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 4, 2025 |
Fourth Amended and Restated Bylaws of Semler Scientific, Inc. Exhibit 3.1 fourth AMENDED AND RESTATED BYLAWS OF SEMLER SCIENTIFIC, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of its registered agent at such address shall be as set forth in the Amended and Restated Certificate of Incorporation of the corporation (as the same may be amended and/or r |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36305 SE |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2025 |
Exhibit 99.1 Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC Campbell, CA – May 13, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended Ma |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 30, 2025 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results Santa Clara, CA – April 30, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is o |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2025 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 111 BTC; Now Holds 3,303 BTC; YTD BTC Yield of 23.5% Santa Clara, CA – April 25, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bit |
|
| April 21, 2025 |
April 21, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| April 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Semler Scientific, Inc. |
|
| April 15, 2025 |
Form of Subordinated Indenture Exhibit 4.2 SEMLER SCIENTIFIC, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.0 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certi |
|
| April 15, 2025 |
Exhibit 1.2 Semler Scientific, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement April 15, 2025 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Barclays Capital Inc. 745 Seventh Avenue New York, NY 10019 Canaccord Genuity LLC One Post Office Square Suite 3000 Boston, MA 02109 Needham & Company, LLC 250 Park Avenue 10th Floor New Y |
|
| April 15, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 15, 2025 Registration No. |
|
| April 15, 2025 |
Exhibit 4.1 SEMLER SCIENTIFIC, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 202[·] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificat |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2025 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our amended and restated certificate of incorporation and our second amended and restated bylaws, both of which h |
|
| February 28, 2025 |
Semler Scientific, Inc. Insider Trading Policy. EXHIBIT 19.1 SEMLER SCIENTIFIC, INC INSIDER TRADING POLICY This memorandum sets forth the policy of Semler Scientific, Inc. (the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the appearance of impropriety, to sa |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Semler Scientific, Inc. |
|
| February 28, 2025 |
Exhibit 10.7 SEMLER SCIENTIFIC, INC. AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, AND ARBITRATION AGREEMENT As a condition of my employment with Semler Scientific, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLE |
|
| February 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| February 18, 2025 |
Exhibit 99.1 Semler Scientific® Reports Fourth Quarter and Full Year 2024 Financial Results with a BTC Yield of 107% since July 1, 2024; Now holds 3,192 BTC Santa Clara, CA – February 18, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the f |
|
| February 4, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| February 4, 2025 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC Activity; Monetizes Minority Investment to Purchase BTC; Purchased Additional 871 BTC; Now Holds 3,192 BTC; YTD BTC Yield of 152.2% Since July 1, 2024 Santa Clara, CA – February 4, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treat |
|
| February 3, 2025 |
EX-24 2 PowerOfAttorney.txt POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| January 28, 2025 |
Exhibit 4.1 SEMLER SCIENTIFIC, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of January 28, 2025 4.25% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01 . Definitions 1 Section 1.02 . References to Interest 15 ARTICLE 2 Issue, Description, Execution, Registration and Exch |
|
| January 28, 2025 |
Form of Confirmation for Capped Call Transactions. Exhibit 10.1 [Dealer name and address] To: Semler Scientific, Inc. 2340-2348 Walsh Avenue, Suite 2344 Santa Clara, CA 95051 From: [Dealer] Re: [Base][Additional] Capped Call Transaction Date: January [ ], 2025 Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Dat |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| January 24, 2025 |
Semler Scientific® Announces Proposed Private Offering of $75.0 Million of Convertible Senior Notes EX-99.1 2 tm254336d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Semler Scientific® Announces Proposed Private Offering of $75.0 Million of Convertible Senior Notes SANTA CLARA, CA – January 23, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR) today announced that it intends to offer, subject to market conditions and other factors, $75.0 million aggregate principal amount of convertible senior notes due 2030 |
|
| January 24, 2025 |
Semler Scientific® Announces Pricing of Upsized Offering of $85.0 Million Convertible Senior Notes Exhibit 99.2 Semler Scientific® Announces Pricing of Upsized Offering of $85.0 Million Convertible Senior Notes SANTA CLARA, CA – January 24, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR) today announced the pricing of its offering of $85.0 million aggregate principal amount of 4.25% convertible senior notes due 2030 (the “notes”) in a private offering (the “offering”) to persons reasonably believ |
|
| January 23, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| January 23, 2025 |
Exhibit 99.1 Semler Scientific® Announces Select Preliminary Unaudited Fourth Quarter 2024 Financial Results and Significant Unrealized Gain from Change in Fair Value of Bitcoin Holdings Santa Clara, CA – January 23, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announc |
|
| January 13, 2025 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC and ATM Activity; Purchased Additional 237 BTC; Now Holds 2,321 BTC; BTC Yield of 99.3% Santa Clara, CA – January 13, 2025 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin (BTC) activi |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| December 16, 2024 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC and ATM Activity; Purchased Additional 211 BTC; Now Holds 2,084 BTC; BTC Yield of 92.8% Santa Clara, CA – December 16, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin (BTC) activ |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| December 16, 2024 |
Up to $50,000,000 Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-280013 PROSPECTUS SUPPLEMENT (To Prospectus dated August 13, 2024) Up to $50,000,000 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, on June 6, 2024 with Cantor Fitzgerald & Co., or Cantor, relating to the sale of shares of our common stock offered by this prospectu |
|
| December 12, 2024 |
SMLR / Semler Scientific, Inc. / Murphy-Chutorian Douglas - SC 13D/A Activist Investment SC 13D/A 1 tm2430859d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Marianne C. Sarrazin, Esq. Goodwin Procter LLP 3 Embarcadero Center San Fr |
|
| December 5, 2024 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC and ATM Activity; Purchased Additional 303 BTC; Now Holds 1,873 BTC; BTC Yield of 78.7% Santa Clara, CA – December 5, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin (BTC) activi |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| November 26, 2024 |
CUSIP No: 81684M104 Exhibit II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock of Semler Scientific, Inc. |
|
| November 26, 2024 |
CUSIP No: 81684M104 EXHIBIT I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 4th day of December, 2012 by Capital Ventures International (hereinafter called “the Company”), whose Registered Office is situated at Windward 1, Regatta Office Park, West Bay Road, Grand Cayman KY1-1103, Cayman Islands, WHEREAS, by agreement dated December 4, 2012, by and between the Company and Susquehanna Advisors Group, Inc. |
|
| November 26, 2024 |
SMLR / Semler Scientific, Inc. / CAPITAL VENTURES INTERNATIONAL - SC 13G Passive Investment CUSIP No: 81684M104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Semler Scientific, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 81684M104 (CUSIP Numbe |
|
| November 25, 2024 |
Exhibit 99.1 Semler Scientific® Announces Updated BTC and ATM Activity Purchased Additional 297 BTC; Now Holds 1,570 BTC; BTC Yield of 58.4% Launches Additional $50.0 million ATM Santa Clara, CA – November 25, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced upda |
|
| November 25, 2024 |
Up to $50,000,000 Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-280013 PROSPECTUS SUPPLEMENT (To Prospectus dated August 13, 2024) Up to $50,000,000 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, on June 6, 2024 with Cantor Fitzgerald & Co., or Cantor, relating to the sale of shares of our common stock offered by this prospectu |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| November 18, 2024 |
Exhibit 99.1 Semler Scientific® Announces BTC and ATM Activity Raised $21.5 million; Purchased Additional 215 BTC; Now Holds 1,273 BTC with BTC Yield of 37.3% Santa Clara, CA – November 18, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bi |
|
| November 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
SMLR / Semler Scientific, Inc. / Murphy-Chutorian Douglas - SC 13D/A Activist Investment SC 13D/A 1 tm2428098d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Marianne C. Sarrazin, Esq. Goodwin Procter LLP 3 Embarcadero Center San Fr |
|
| November 5, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Semler Scientific, Inc. |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3630 |
|
| November 5, 2024 |
As filed with the Securities and Exchange Commission on November 5, 2024 As filed with the Securities and Exchange Commission on November 5, 2024 Registration No. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| November 4, 2024 |
Semler Scientific® Reports Third Quarter 2024 Financial Results and Additional Bitcoin Purchases Exhibit 99.1 Semler Scientific® Reports Third Quarter 2024 Financial Results and Additional Bitcoin Purchases Santa Clara, CA – November 4, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the third quarter ended September 30, 2024. In additi |
|
| October 8, 2024 |
Exhibit 10.4 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER SEMLER SCIENTIFIC, INC. 2024 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share:$ [FMV on Grant Date] Grant Date: Expiration Date: [No more than 10 years] Pursuant to the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan as amended through the date here |
|
| October 8, 2024 |
Exhibit 10.5 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES AND CONSULTANTS UNDER THE SEMLER SCIENTIFIC, INC. 2024 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Semler Scientific, Inc. (the “Company”) hereby grants |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| October 8, 2024 |
Exhibit 10.2 INCENTIVE STOCK OPTION AGREEMENT UNDER THE SEMLER SCIENTIFIC, INC. 2024 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share:$ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: Expiration Date: [up to 10 years (5 if a 10% owner)] Pursuant to the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan as amended through |
|
| October 8, 2024 |
Semler Scientific, Inc. 2024 Stock Option and Incentive Plan. Exhibit 10.1 SEMLER SCIENTIFIC, INC. 2024 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Semler Scientific, Inc. (the “Company”) and its Affil |
|
| October 8, 2024 |
Exhibit 10.6 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE SEMLER SCIENTIFIC, INC. 2024 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Semler Scientific, Inc. (the “Company”) hereby grants an award of |
|
| October 8, 2024 |
Exhibit 10.3 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES AND CONSULTANTS UNDER THE SEMLER SCIENTIFIC, INC. 2024 STOCK OPTION AND Incentive PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share:$ [FMV on Grant Date] Grant Date: Expiration Date: Pursuant to the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “ |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| August 26, 2024 |
Semler Scientific Announces Additional Bitcoin Purchases Exhibit 99.1 Semler Scientific Announces Additional Bitcoin Purchases Santa Clara, Calif. – August 26, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it has purchased an additional 83 bitcoins for $5.0 million in cash, inclusive of fees and expenses. As of |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 12, 2024 |
August 12, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36305 SEM |
|
| August 5, 2024 |
Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases Exhibit 99.1 Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases Santa Clara, CA – August 5, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the second quarter ended June 30, 2024. In addition, t |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| July 31, 2024 |
NYDIG Digital Asset Custodial Agreement Exhibit 99.2 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Digital Asset Custodial Term Sheet Effective Date May 23, 2024 Custodian NYDIG Trust Company LLC, a duly chartered New York limited liability trust company Client [Legal name of customer], a [st |
|
| July 31, 2024 |
As filed with the Securities and Exchange Commission on July 31, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| July 31, 2024 |
Goodwin Procter LLP Three Embarcadero Center, 28th Floor San Francisco, CA 94111 goodwinlaw. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorpor |
|
| July 31, 2024 |
Bitcoin Strategy Related Supplemental Disclosures Exhibit 99.1 Bitcoin Strategy Related Supplemental Disclosures Bitcoin Treasury Strategy WE ARE NOT REGISTERED AS AN INVESTMENT COMPANY UNDER THE INVESTMENT COMPANY ACT OF 1940 AND STOCKHOLDERS DO NOT HAVE THE PROTECTIONS ASSOCIATED WITH OWNERSHIP OF SHARES IN A REGISTERED INVESTMENT COMPANY NOR THE PROTECTIONS AFFORDED BY THE COMMODITIES EXCHANGE ACT. Summary This section summarizes our current a |
|
| July 31, 2024 |
Coinbase Prime Broker Agreement Exhibit 99.3 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL COINBASE PRIME BROKER AGREEMENT General Terms and Conditions 1. Introduction 1.1 This agreement dated as of (the “Effective Date”) (including, the Coinbase Custody Services Agreement attached he |
|
| July 11, 2024 |
As filed with the Securities and Exchange Commission on July 11, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 11, 2024 Registration No. |
|
| July 11, 2024 |
Bitcoin Strategy Related Supplemental Disclosures Exhibit 99.1 Bitcoin Strategy Related Supplemental Disclosures Bitcoin Treasury Strategy WE ARE NOT REGISTERED AS AN INVESTMENT COMPANY UNDER THE INVESTMENT COMPANY ACT OF 1940 AND STOCKHOLDERS DO NOT HAVE THE PROTECTIONS ASSOCIATED WITH OWNERSHIP OF SHARES IN A REGISTERED INVESTMENT COMPANY NOR THE PROTECTIONS AFFORDED BY THE COMMODITIES EXCHANGE ACT. Summary This section summarizes our current a |
|
| July 11, 2024 |
Goodwin Procter LLP Three Embarcadero Center, 28th Floor San Francisco, CA 94111 goodwinlaw. |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 6, 2024 |
Exhibit 4.1 SEMLER SCIENTIFIC, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 202[·] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificat |
|
| June 6, 2024 |
Form of Subordinated Indenture Exhibit 4.2 SEMLER SCIENTIFIC, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.0 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certi |
|
| June 6, 2024 |
Sales Agreement, dated June 6, 2024, by and between the registrant and Cantor Fitzgerald & Co. Exhibit 1.2 Semler Scientific, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement June 6, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Semler Scientific, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Is |
|
| June 6, 2024 |
As filed with the Securities and Exchange Commission on June 6, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 6, 2024 Registration No. |
|
| June 6, 2024 |
Bitcoin Strategy Related Supplemental Disclosures Exhibit 99.1 Bitcoin Strategy Related Supplemental Disclosures Bitcoin Treasury Strategy Summary This section summarizes our current acquisition strategy for bitcoin, including our historical purchases, trading execution, custody, storage, and accounting considerations. We reserve the right to update and alter our acquisition strategy from time to time. We view bitcoin as a reliable store of value |
|
| June 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Semler Scientific, Inc. |
|
| May 28, 2024 |
Semler Scientific® Announces Bitcoin Treasury Strategy Exhibit 99.1 Semler Scientific® Announces Bitcoin Treasury Strategy Santa Clara, CA – May 28, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, announced today that its board of directors has adopted bitcoin as its primary treasury reserve asset. In addition, Semler Scientific an |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36305 SE |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2024 |
Semler Scientific® Reports First Quarter 2024 Financial Results Exhibit 99.1 Semler Scientific® Reports First Quarter 2024 Financial Results 2024 Q1 highlights compared to the corresponding period of 2023: ●First quarter revenues were $15.9 million, a decrease of 13% ●First quarter net income was $6.1 million, an increase of 22% ●Cash, cash equivalents and restricted cash balance increased to $62.9 million Santa Clara, CA – May 7, 2024 – Semler Scientific, Inc |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLE |
|
| March 7, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our amended and restated certificate of incorporation and our second amended and restated bylaws, both of which h |
|
| March 7, 2024 |
Employment agreement dated May 2, 2022 by and among Semler Scientific, Inc. and Renae Cormier. Exhibit 10.7 SEMLER SCIENTIFIC, INC. AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, AND ARBITRATION AGREEMENT As a condition of my employment with Semler Scientific, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company |
|
| March 7, 2024 |
Exhibit 97.1 SEMLER SCIENTIFIC, INC COMPENSATION RECOVERY POLICY Adopted as of October 19, 2023 Semler Scientific, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (a |
|
| March 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| March 5, 2024 |
Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results 2023 Q4 and full year highlights compared to the corresponding period of 2022: ●Fourth quarter revenues were $15.1 million, an increase of 9% ●Fourth quarter net income was $4.2 million, an increase of 31% ●Full year revenues were $68.2 million, an increase of 20% ●Full year net income was $20.6 million, an |
|
| February 12, 2024 |
SMLR / Semler Scientific, Inc. / Topline Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d775482dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Semler Scientific, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 81684M104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of Statement) Check the appropriate box to desi |
|
| February 12, 2024 |
EX-99.A 2 d775482dex99a.htm EX-99.A EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3630 |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Semler Scientific Reports Third Quarter and Year-to-Date 2023 Financial Results Exhibit 99.1 Semler Scientific Reports Third Quarter and Year-to-Date 2023 Financial Results 2023 Q3 highlights: ●Revenue of $16.3 million, an increase of 16% compared to the corresponding period of 2022 ●Net income of $5.5 million, an increase of 50% compared to the corresponding period of 2022 ●Quarter-ending cash, cash equivalents and short-term investments of $56.0 million Santa Clara, CA – No |
|
| October 23, 2023 |
Exhibit 3.1 Page 1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “SEMLER SCIENTIFIC, INC.”, FILED IN THIS OFFICE ON THE NINETEENTH DAY OF OCTOBER, A.D. 2023, AT 2:19 O`CLOCK P.M. 5404039 8100Authentication: 204414749 SR# 20233771415Date: 10-19-23 You may verif |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| September 14, 2023 |
SMLR / Semler Scientific Inc / SEMLER ERIC - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Semler Scientific, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M104 (CUSIP Number) ERIC SEMLER c |
|
| September 14, 2023 |
EX-99.1 2 ex991to13da210608006091423.htm JOINT FILING AGREEMENT, DATED SEPTEMBER 14, 2023 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common st |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 14, 2023 |
Exhibit 10.3 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Doug Murphy-Chutorian (“Employee”) and Semler Scientific, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee began serving as the Company’s Chief Exe |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36305 SEM |
|
| August 14, 2023 |
Exhibit 10.4 INTERIM EMPLOYMENT AGREEMENT This Interim Employment Agreement (“Agreement”) is made by and between Doug Murphy-Chutorian (“Employee”) and Semler Scientific, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee is currently employed by the Company; WHEREAS, Employee entered into an At-Will Employment, Con |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2023 |
Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results Exhibit 99.1 Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results 2023 Q2 highlights: ●Revenue was $18.6 million, an increase of 25% compared to the corresponding period of 2022 ●Net income was $5.9 million, an increase of 44% compared to the corresponding period of 2022 ●Cash, cash equivalents and short-term investments of $51.8 million Santa Clara, CA – August 10, 20 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2023 |
Exhibit 99.1 Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining Santa Clara, CA – July 11, 2023 – Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief f |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 17, 2023 |
SMLR / Semler Scientific Inc / Murphy-Chutorian Douglas - SC 13D/A Activist Investment SC 13D/A 1 tm2316043d3sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Marianne C. Sarrazin, Esq. Goodwin Procter LLP 3 Embarcadero Center San Fr |
|
| May 17, 2023 |
Exhibit 10.1 WARRANT REPURCHASE AGREEMENT This Warrant Repurchase Agreement (this “Agreement”) is made as of May 16, 2023, by and between Semler Scientific, Inc., a Delaware corporation (the “Company”), and the undersigned holder of warrants to purchase shares of the Company’s capital stock (the “Warrantholder,” and together with the Company, the “Parties”). WHEREAS, the Warrantholder had purchase |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36305 SEM |
|
| May 12, 2023 |
Employment Agreement with Wayne T. Pan dated March 29, 2023 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT In consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, this Employment Agreement (“Agreement”) is made between Semler Scientific, Inc. (the “Company”) and Wayne T. Pan (“Executive”). The Company and Executive are referred to collectiv |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 10, 2023 |
Semler Scientific Reports First Quarter 2023 Financial Results Exhibit 99.1 Semler Scientific Reports First Quarter 2023 Financial Results 2023 Q1 highlights: ●Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022 ●Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022 ●Cash, cash equivalents and short-term investments of $43.0 million Santa Clara, CA – May 10, 2023 – Semler Scientific |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 11) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Marianne C. Sarrazin, Esq. Goodwin Procter LLP 3 Embarcadero Center San Francisco, CA 94111 Telephone |
|
| April 20, 2023 |
SMLR / Semler Scientific Inc / SEMLER ERIC - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Semler Scientific, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M104 (CUSIP Number) Eric Semler c |
|
| April 19, 2023 |
Exhibit 3.1 Third AMENDED AND RESTATED BYLAWS OF SEMLER SCIENTIFIC, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of its registered agent at such address shall be as set forth in the Amended and Restated Certificate of Incorporation of the corporation (as the same may be amended and/or re |
|
| April 19, 2023 |
Cooperation Agreement, dated April 19, 2023, by and among Semler Scientific, Inc. and the Investors Exhibit 10.1 AGREEMENT This Agreement (this “Agreement”) is made and entered into as of April 19, 2023 by and among Semler Scientific, Inc., a Delaware corporation (the “Company”) and Eric Semler and William H.C. Chang (each, an “Investor” and collectively, the “Investors”). The Company and each of the Investors are collectively herein referred to as the “Parties” and individually as a “Party.” RE |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| April 17, 2023 |
Exhibit 99.1 NASDAQ:SMLR Needham Virtual Healthcare Conference April 2023 Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believe,” “estimate,” “anticipate,” “expect,” “plan,” “intend,” “may,” “c |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| March 23, 2023 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our amended and restated certificate of incorporation and our second amended and restated bylaws, both of which h |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLE |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2023 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2023 |
Semler Scientific Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Semler Scientific Reports Fourth Quarter and Full Year 2022 Financial Results 2022 Q4 and Full Year highlights compared to the corresponding period of 2021: ●Fourth quarter revenue was $13.8 million, an increase of 20% ●Fourth quarter net income was $3.2 million, an increase of 113% ●Full year revenue was $56.7 million, an increase of 7% ●Full year net income was $14.3 million, a decr |
|
| February 15, 2023 |
SMLR / Semler Scientific Inc / Topline Capital Management, LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) Semler Scientific, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 81684M104 (CUSIP Number) February 10, 2023 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 15, 2023 |
EX-99.A EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties. Dated: February 15, |
|
| February 14, 2023 |
SMLR / Semler Scientific Inc / Park West Asset Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SEMLER SCIENTIFIC, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 81684M104 (CUSIP Number) DECEMBER 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 10) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Marianne C. Sarrazin, Esq. Goodwin Procter LLP 3 Embarcadero Center San Francisco, CA 94111 Telephone: (415) 733-60 |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36305 |
|
| November 1, 2022 |
Semler Reports Third Quarter and Year-to-Date 2022 Financial Results Exhibit 99.1 Semler Reports Third Quarter and Year-to-Date 2022 Financial Results 2022 Q3 quarterly HIGHLIGHTS compared to the corresponding period of 2021: ? ?Revenue was $14.0 million, same as the prior year period ?Net income was $3.7 million, or $0.55 per basic share and $0.46 per diluted share, compared to $4.2 million, or $0.61 per basic share and $0.51 per diluted share ?Cash and cash equiv |
|
| November 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 1, 2022 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (C |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Marianne C. Sarrazin, Esq. Goodwin Procter LLP 3 Embarcadero Center San Francisco, CA 94111 Telephone: (415) 733-600 |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| September 9, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2022 |
Semler Reports Second Quarter and First Half of 2022 Financial Results Exhibit 99.1 Semler Reports Second Quarter and First Half of 2022 Financial Results 2022 Q2 quarterly HIGHLIGHTS compared to the corresponding period of 2021: ●Revenues were $14.8 million, an increase of 4%, compared to $14.3 million ●Net income was $4.1 million, or $0.60 per basic share and $0.51 per diluted share, compared to $6.7 million, or $1.00 per basic share and $0.83 per diluted share ●Ca |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 2, 2022 |
Semler Reports First Quarter 2022 Financial Results Exhibit 99.1 Semler Reports First Quarter 2022 Financial Results 2022 Q1 HIGHLIGHTS compared to the corresponding period of 2021: ? ?Revenues were $14.0 million, an increase of $0.8 million, or 6%, compared to $13.2 million ?Net income was $3.4 million, or $0.50 per basic share and $0.41 per diluted share, compared to $4.9 million, or $0.73 per basic share and $0.60 per diluted share ?Cash at Marc |
|
| May 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| March 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Semler Scientific’s Board of Directors authorizes an up to $20.0 million stock repurchase program Exhibit 99.1 Semler Scientific?s Board of Directors authorizes an up to $20.0 million stock repurchase program SANTA CLARA, Calif., March 14, 2022 - Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its board of directors has authorized a $20.0 million stock repurch |
|
| March 7, 2022 |
Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Semler Scientific, Inc. |
|
| March 7, 2022 |
As filed with the Securities and Exchange Commission on March 7, 2022 As filed with the Securities and Exchange Commission on March 7, 2022 Registration No. |
|
| March 4, 2022 |
? Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our amended and restated certificate of incorporation and our second amended and restated bylaws, both of which |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Co |
|
| February 28, 2022 |
Semler Reports Fourth Quarter and Year-to-Date 2021 Financial Results Exhibit 99.1 Semler Reports Fourth Quarter and Year-to-Date 2021 Financial Results 2021 HIGHLIGHTS compared to 2020: ?Annual revenues increased by 37% ?Net income increased by 23% ?Cash at December 31, 2021 increased to $37.3 million from $22.1 million ? Santa Clara, CA ? February 28, 2022 ? Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinica |
|
| February 14, 2022 |
SMLR / Semler Scientific Inc / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, PAR VALUE $0.001 per share (Title of Class of Securities) 81684M104 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
SMLR / Semler Scientific Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Com |
|
| November 1, 2021 |
Semler Reports Third Quarter and Year-to-Date 2021 Financial Results ? Exhibit 99.1 Semler Reports Third Quarter and Year-to-Date 2021 Financial Results HIGHLIGHTS - Year-to-Date 2021 compared to the corresponding period of 2020: ? ? Revenues were $41.5 million, an increase of 56% compared to $26.5 million ? Pre-tax net income of $17.7 million, an increase of $7.7 million, or 77% compared to $10.0 million ? Net income was $15.7 million, an increase of $7.1 million, |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| October 26, 2021 |
Exhibit 3.1 Second AMENDED AND RESTATED BYLAWS OF SEMLER SCIENTIFIC, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of its registered agent at such address shall be as set forth in the Amended and Restated Certificate of Incorporation of the corporation (as the same may be amended and/or r |
|
| September 27, 2021 |
Form 8-A filed on September 27, 2021 8-A12B 1 tm2128264d18a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Semler Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State or other jurisdiction of incorporation or organization |
|
| September 10, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 2, 2021 |
Semler Reports Second Quarter and First Half of 2021 Financial Results ? Exhibit 99.1 Semler Reports Second Quarter and First Half of 2021 Financial Results 2021 Q2 HIGHLIGHTS compared to the corresponding period of 2020: ? ? Revenues were $14.3 million, an increase of 125% compared to $6.4 million ? Pre-tax net income of $6.5 million, an increase of $5.5 million, or 554%, compared to $1.0 million ? Net income was $6.7 million, or $1.00 per basic share and $0.83 per |
|
| August 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 3, 2021 |
Semler Reports First Quarter 2021 Financial Results Exhibit 99.1 Semler Reports First Quarter 2021 Financial Results 2021 Q1 HIGHLIGHTS compared to the corresponding period of 2020: ? Revenues were $13.2 million, an increase of 40% ? Pre-tax net income of $6.0 million, an increase of $2.5 million, or 74%, compared to $3.5 million ? Net income was $4.9 million, or $0.73 per basic share and $0.60 per diluted share, compared to $2.7 million, or $0.41 |
|
| May 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| March 9, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| March 1, 2021 |
Semler Reports Record Fourth Quarter and Year End 2020 Financial Results Exhibit 99.1 Semler Reports Record Fourth Quarter and Year End 2020 Financial Results 2020 HIGHLIGHTS compared to 2019: · Annual revenues increased by 18% · Pre-tax net income of $16.5 million, an increase of $5.8 million, or 54%, compared to $10.7 million · Net income of $14.0 million, a decrease of $1.1 million, or 7%, compared to $15.1 million (which included a $4.4 million income tax benefit) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, PAR VALUE $0.001 per share (Title of Class of Securities) 81684M104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 81684M104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 81684M104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissi |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36305 |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| November 5, 2020 |
Semler Reports Record Third Quarter and Year-to-Date 2020 Financial Results Exhibit 99.1 Semler Reports Record Third Quarter and Year-to-Date 2020 Financial Results 2020 Q3 HIGHLIGHTS compared to Q2 2020: · Revenues were $10,727,000, an increase of $4,354,000, or 68%, compared to $6,373,000 · Pre-tax net income of $5,595,000, an increase of $4,605,000, or 465%, compared to $990,000 · Net income was $4,866,000, or $0.74 per basic share and $0.61 per diluted share, compared |
|
| October 23, 2020 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| September 11, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36305 SEML |
|
| August 3, 2020 |
Semler Reports Second Quarter and First Half 2020 Financial Results Exhibit 99.1 Semler Reports Second Quarter and First Half 2020 Financial Results 2020 Q2 HIGHLIGHTS compared to the corresponding period of 2019: · Revenues were $6,373,000, a decrease of 20% · Pre-tax net income was $990,000, a decrease of $1,706,000 · Net income was $0.16 per basic share and $0.13 per diluted share, compared to $0.41 per basic share and $0.32 per diluted share · Cash at June 30, |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36305 SEMLER SCIENTIFIC, IN |
|
| May 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 4, 2020 |
Semler Reports First Quarter 2020 Financial Results Exhibit 99.1 Semler Reports First Quarter 2020 Financial Results 2020 Q1 HIGHLIGHTS compared to the corresponding period of 2019: · Revenues were $9,430,000, which is an increase of 39% · Pre-tax net income of $3,450,000, an increase of $1,596,000, or 86%, compared to $1,854,000 · Net income grew to $0.41 per basic share and $0.33 per diluted share, compared to $0.29 per basic share and $0.23 per |
|
| March 30, 2020 |
SMLR / Semler Scientific, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 81684M104 (CUSIP Number) March 23, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ |
|
| March 9, 2020 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our certificate of incorporation and bylaws, both of which have been publicly filed with the Securities and Excha |
|
| March 9, 2020 |
SMLR / Semler Scientific, Inc. 10-K - Annual Report - 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to SEM |
|
| March 3, 2020 |
Semler Reports Record Fourth Quarter and Year End 2019 Financial Results Exhibit 99.1 Semler Reports Record Fourth Quarter and Year End 2019 Financial Results 2019 HIGHLIGHTS compared to 2018: · Annual revenues increased by 52% · Pre-tax income of $10,701,000, an increase of $5,661,000, or 112%, compared to $5,040,000 · Net income after tax grew to $2.34 per basic share and $1.88 per diluted share, compared to $0.82 per basic share and $0.66 per diluted share · Income |
|
| March 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2020 |
SMLR / Semler Scientific, Inc. / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 81684M104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Yvan-Claude Pierre, Esq. Marianne C. Sarrazin, Esq. Cooley LLP 55 Hudson Yards New York, New York 10001-2157 Telepho |
|
| November 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2019 |
Exhibit 10.1 WARRANT REPURCHASE AGREEMENT This Warrant Repurchase Agreement (this “Agreement”) is made as of November 6, 2019, by and between Semler Scientific, Inc., a Delaware corporation (the “Company”), and the undersigned holder of warrants to purchase shares of the Company’s capital stock (the “Warrantholder,” and together with the Company, the “Parties”). WHEREAS, the Company has granted to |
|
| November 8, 2019 |
SMLR / Semler Scientific, Inc. / Murphy-Chutorian Douglas - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Yvan-Claude Pierre, Esq. Marianne C. Sarrazin, Esq. Cooley LLP 55 Hudson Yards New York, New York 10001-2157 Telepho |
|
| November 6, 2019 |
SMLR / Semler Scientific, Inc. 10-Q - Quarterly Report - FROM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36305 SEMLER SCIENTIFIC |
|
| October 30, 2019 |
Semler Reports Record Third Quarter and Year-to-Date 2019 Financial Results Exhibit 99.1 Semler Reports Record Third Quarter and Year-to-Date 2019 Financial Results 2019 Q3 HIGHLIGHTS compared to the corresponding period of 2018: · Revenues were $8,902,000, an increase of 60% · Pre-tax income of $3,108,000, an increase of $1,640,000, or 112%, compared to $1,468,000 · Net income grew to $1.20 per basic share and $0.96 per diluted share, compared to $0.24 per basic share an |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2019 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commissio |
|
| October 3, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| August 30, 2019 |
SMLR / Semler Scientific, Inc. DEF 14A - - DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 2, 2019 |
SMLR / Semler Scientific, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36305 SEMLER SCIENTIFIC, INC |
|
| July 26, 2019 |
Semler Reports Record Second Quarter and First Half 2019 Financial Results Exhibit 99.1 Semler Reports Record Second Quarter and First Half 2019 Financial Results 2019 Q2 HIGHLIGHTS compared to the corresponding period of 2018: · Revenues were $7,953,000, an increase of 45% · Net income grew to $0.41 per basic share and $0.32 per diluted share, compared to $0.24 per basic share and $0.19 per diluted share · Cash at June 30, 2019 increased to $4,182,000 from $2,009,000 Sa |
|
| July 26, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2019 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2019 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2019 |
Exhibit 10.1 WARRANT REPURCHASE AGREEMENT This WARRANT REPURCHASE AGREEMENT (this “Agreement”) is made as May 3, 2019, by and between Semler Scientific, Inc., a Delaware corporation (the “Company”), and the undersigned holder of warrants to purchase shares of the Company’s capital stock (the “Warrantholder,” and together with the Company, the “Parties”). WHEREAS, the Company has granted to the War |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Yvan-Claude Pierre, Esq. Marianne C. Sarrazin, Esq. Cooley LLP 55 Hudson Yards New York, New York 10001-2157 Telepho |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 SEMLER SCIENTIFIC, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81684M 104 (CUSIP Number) Yvan-Claude Pierre, Esq. Marianne C. Sarrazin, Esq. Cooley LLP 55 Hudson Yards New York, New York 10001-2157 Telepho |
|
| May 7, 2019 |
SMLR / Semler Scientific, Inc. 10-Q/A Quarterly Report 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36305 SEM |
|
| May 3, 2019 |
SMLR / Semler Scientific, Inc. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36305 SEMLER SCIENTIFIC, IN |
|
| April 29, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2019 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36305 26-1367393 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2019 |
Semler Reports First Quarter 2019 Financial Results Exhibit 99.1 Semler Reports First Quarter 2019 Financial Results 2019 Q1 HIGHLIGHTS compared to the corresponding period of 2018: · Revenue was $6,761,000, which is an increase of 51% · Net income grew to $0.29 per basic share and $0.23 per diluted share, compared to $0.12 per basic and 0.10 per diluted share · Cash at March 31, 2019 increased to $4,544,000 from $419,000 one year ago San Jose, Cal |
|
| March 7, 2019 |
SMLR / Semler Scientific, Inc. FORM 10-K (Annual Report) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to SEM |
